-

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

NEW YORK--(BUSINESS WIRE)--Massive Bio, a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI), a premier provider of cutting-edge cancer care. This strategic alliance aims to redefine the landscape of cancer treatment by harnessing advanced AI technology and establishing an extensive nationwide network.

Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine. By leveraging sophisticated algorithms and comprehensive diagnostic information, Massive Bio will empower patients and ordering physicians at TOI with clinical decision-support and clinical trial matching services.

Cristina Green, Vice President of Clinical Research, shared her enthusiasm for this partnership, stating, "This collaboration with Massive Bio complements our ability to connect patients with advanced cancer therapies and cutting-edge clinical trials. By leveraging AI-driven precision medicine, we are confident that this partnership will accelerate breakthroughs in cancer research and deliver life-changing treatment options to our patients."

"We are incredibly excited about joining forces with The Oncology Institute," said Selin Kurnaz, Ph.D., CEO of Massive Bio. "This partnership will not only revolutionize cancer care but will also empower patients with access to the most advanced precision medicine available. Our combined expertise will open new doors for patients, connecting them to potentially life-saving treatments and groundbreaking clinical trials."

Furthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023. Dr. Arturo Loaiza-Bonilla, renowned oncologist and a key figure in the development of the chatbot technology, stated, "We are proud to be part of this innovative partnership between Massive Bio and TOI. The integration of AI-driven chatbots with clinical decision-support tools will revolutionize the way researchers access and analyze oncology data, enabling more efficient and impactful research initiatives, and will bolster this newly forged alliance to the betterment of all cancer patients."

The alliance between Massive Bio and TOI represents a paradigm shift in cancer care, combining the power of advanced AI technology, personalized therapy, and an extended network of research collaborations. Together, these industry leaders are poised to reshape the future of oncology and bring new hope to patients and their families.

About Massive Bio:

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

About TOI

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 700 teammates in over 60 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Contacts

For media inquiries:

Media:
Erkan Terzi
Chief Marketing Officer
+1 844 627 7246
pr@massivebio.com

The Oncology Institute, Inc.:
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125

Investors:
Solebury Trout
Maria Lycouris
mlycouris@soleburytrout.com

Massive Bio


Release Versions

Contacts

For media inquiries:

Media:
Erkan Terzi
Chief Marketing Officer
+1 844 627 7246
pr@massivebio.com

The Oncology Institute, Inc.:
Daniel Virnich, MD
danielvirnich@theoncologyinstitute.com
(562) 735-3226 x 81125

Investors:
Solebury Trout
Maria Lycouris
mlycouris@soleburytrout.com

More News From Massive Bio

Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and Optellum, the leader in AI-enabled lung cancer diagnosis and the developer of the world’s first FDA-cleared clinical decision support software for early-stage lung cancer, today announced a collaboration to bridge early lung cancer detection with clinical trial access for patients with non-small cell lung cancer (NSCLC). The collaboratio...

Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026

CHICAGO--(BUSINESS WIRE)--Massive Bio today announced the next-generation product suite within Reticulum Nexus™, introducing a coordinated set of AI agents, intelligent calculators, signal engines, patient navigation tools, and physician referral workflows designed to move oncology access from fragmented trial matching to closed-loop orchestration. The new suite brings together Patient Connect™, TrialRelay™, NexusPulse™, Sentinel Agents™, DrArturo AI™, and Phoebe AI™ into a real-time multi-agen...

Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global precision oncology company, today announced a new partnership with TOUCH, The Black Breast Cancer Alliance (TOUCH BBCA), a breast cancer patient advocacy organization, and Navigating Trials, a clinical trial navigation platform serving patients across all cancer types. Through this collaboration, Massive Bio's AI-powered trial matching will be made available directly within both organizations' digital platforms, giving their patient commu...
Back to Newsroom